Lung Cancer Surgery Market

The global Lung Cancer Surgery Market is valued at USD 6.12 Billion in 2024 and is projected to reach a value of USD 9.80 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.4% between 2025 and 2035.

Key Insights

• With 35.2% market share, surgical instruments dominated the market in 2024 owing to continual advancements in surgical technologies, including minimally invasive techniques and robotic-assisted surgeries
• In 2024,thoracotomy held a market share of 63.3% due to its effectiveness in accessing and treating lung tumors and its versatility in addressing various stages and types of lung cancer
• In 2024, North America led the market, capturing 36.2% of the total revenue due to advanced healthcare infrastructure, high adoption rates of advanced surgical techniques, and robust research and development initiatives aimed at improving treatment outcomes and patient care
• The Asia Pacific region is expected to experience significant growth, with a significant CAGR projected over the forecast period

How has the market grown over the past five years in North America and what are the projected growth rates?

North America achieves a dominant 36.2% share of sales in 2024 due to a rising number of individuals suffering from lung cancer alongside an aging population

The regions developed healthcare infrastructure, high healthcare expenditures, and the presence of major market participants are all factors contributing to its dominance. The high rate of adoption of cutting-edge surgical technologies and strategies in this region is similarly supported through the availability of particularly qualified surgeons and modern medical facilities.

Lung cancer cases have increased significantly in nations like the US and Canada, which has accelerated demand for sophisticated surgical procedures. For instance, according to the American Cancer Societys 2023 report, the majority of lung cancer diagnoses occur in individuals aged 65 and above, with the average age at diagnosis poised around 70 years.

The endorsement of new products in the United States contributes significantly to the markets expansion. Each year, tens of thousands of people are cured of non-small cell lung cancer (NSCLC) in the United States. Notably, in May 2021, Amgen announced the United States FDAs approval of LUMAKRAS (sotorasib) for the treatment of adult patients afflicted with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. This approval, contingent upon an FDA-approved test, extends to patients who have undergone at least one prior systemic therapy.

What are the anticipated trends and innovations expected to shape the Surgical Instruments segment in the market over the forecast period?

Surgical Instruments segment dominating the market with a 35.2% share in 2024 because they are essential for performing precise and effective lung cancer surgeries

Surgical Instruments includes a wide range of instruments such as scalpels, forceps, retractors, and scissors used in many different types of lung cancer procedures, such as wedge resection, pneumonectomy, and lobectomy. Continuous technical improvements in surgical tools, which enable accurate and minimally invasive treatments, are the driving force behind this markets predominance. Due to the vital role these tools play in both conventional and minimally invasive surgical procedures, this segment is dominating. These tools are widely used because of their precision and dependability, which are essential for the effective removal of cancerous tissues.

Ongoing innovations and technological advancements are driving the Surgical Instruments segments expansion. To increase surgical accuracy and patient outcomes, manufacturers are always refining the form and function of these tools. For instance, the US Medical System states that researchers are developing smart devices that are integrated with sensors that can identify different kinds of tissue, including the difference between healthy and malignant tissues. The application of this innovative technology is expected to improve the precision and effectiveness of surgical interventions by enabling the exact targeting of particular tissue types during microsurgical procedures. Additionally, in November 2023, Surtex Instruments, a leading manufacturer of surgical instruments, unveiled its groundbreaking "Infinex" series during the MEDICA 2023 exhibition. Specifically created for microsurgery, this cutting-edge series aims to give surgeons unparalleled control and precision even while going through the complexities of the most difficult surgical operations.

The introduction of ergonomic designs, improved material durability, and enhanced safety features are some of the key developments driving the market. Additionally, the increasing focus on minimally invasive techniques, which require specialized instruments, is also boosting the demand within this segment. Surgeons are increasingly opting for these advanced instruments to perform complex procedures with higher accuracy and reduced recovery times for patients.

Are Global Initiatives Revolutionizing Breakthroughs in Cancer Care?

• The Production Linked Incentives (PLI) Scheme for Medical Devices manufacturing aims to provide financial incentives to bolster domestic production and entice substantial investment in various segments of medical devices. These segments encompass critical areas such as cancer care devices, radiology and imaging devices, anaesthetics devices, implants, among others. The scheme allocates Production Linked Incentives amounting to $456 million, with the overarching goal of fostering the emergence of Indian enterprises as global leaders and advancing the "Make in India, Make for the World" initiative.
• The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) is a significant health insurance scheme in India, offering coverage of up to INR 5 lakhs per family per year for a wide range of medical treatments, including cancer-related care.
• In 2024, the Health Resources and Services Administration (HRSA) is enhancing its Accelerating Cancer Screening (AxCS) Initiative with an additional $10 million investment for the Alcee L. Hastings Program for Advanced Cancer Screening, bringing the total program funding to over $25 million within three years.
• The Canadian Pain Task Force (CPTF) was established to provide guidance and insights to Health Canada on improving chronic pain prevention and management strategies. In January 2021, the CPTFs mandate was revitalized to expedite recommendations on priority actions, focusing on supporting individuals with pain and addressing pain management across Canada.
• The National Health Security Office (NHSO) has approved a budget allocation of 60 million baht to provide robotic surgery for 600 patients diagnosed with prostate, colorectal, liver, pancreatic, or bile duct cancer.

Transformative Trends in Lung Cancer Surgery

• Theres a growing preference for minimally invasive surgical techniques such as video-assisted thoracic surgery (VATS) and robotic-assisted surgery. These approaches offer benefits such as smaller incisions, reduced blood loss, shorter hospital stays, and quicker recovery times compared to traditional open surgeries.
• Advances in molecular profiling and genetic testing are enabling the emergence of personalized treatment approaches. Targeted therapies and immunotherapies are being increasingly used in conjunction with surgery to tailor treatment plans based on the individual characteristics of the patients tumor.
• Robotic-assisted surgical systems are gaining traction in lung cancer surgery due to their precision, dexterity, and enhanced visualization capabilities. Surgeons are leveraging these systems to perform complex procedures with greater accuracy, leading to improved patient outcomes.
• Theres a shift towards patient-centered care models that prioritize patient preferences, quality of life, and holistic well-being. Surgeons are increasingly involving patients in treatment decision-making processes and providing comprehensive support services to address their physical, emotional, and psychosocial needs throughout the treatment journey.

Is the Lung Cancer Market Poised for Growth with Rising Prevalence, Innovative Treatments, and Strategic Collaborations?

The increasing prevalence of lung cancer, rising pollution from rapid industrialization, a growing number of smokers, and increased funding for R&D of new drugs drives the Lung Cancer Surgery market. For instance, according to the American Cancer Society (ACS) data published in 2022, lung cancer (both small and non-small cell) is the second most common cancer in both men and women, accounting for nearly 25% of all cancer deaths. Additionally, the American Lung Associations 2022 report noted that while lung cancer remains the leading cause of cancer deaths among men and women, the national survival rate has increased from 21% to 25% over the past five years, though it remains lower among communities of color at 20%.

Surgical interventions have resulted from early diagnosis and enhanced screening techniques like low-dose computed tomography (LDCT), which have also raised the detection rate. Furthermore, the market for lung cancer surgeries has increased due to improvements in minimally invasive procedures like video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries, which are an instance of minimally invasive surgical methods and technology.

Furthermore, acquisitions, partnerships, mergers, and collaborations among key players are also propelling market growth. For instance, in May 2021, Janssen Pharmaceutical announced that the U.S. FDA granted accelerated approval for RYBREVANTTM (amivantamab-vmjw) for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed after platinum-based chemotherapy. Such product approvals are crucial in driving the market and are expected to continue contributing to its growth over the forecast period.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

How Are Market Dynamics Shaping the Future of Industry Growth?

Rising global incidence of lung cancer drives the market growth

Lung cancer ranks as the second most common cancer globally. It is the most prevalent cancer among men and the second most common among women. For instance, according to the World Health Organization (WHO), there were 2.21 million new lung cancer cases worldwide and 1.80 million deaths attributed to the disease. It is the second most frequent cancer in women and the most common in men. For instance, the World Health Organization (WHO) reports that 1.80 million fatalities and 2.21 million new cases of lung cancer were reported globally. High smoking rates, which are the primary cause of lung cancer, as well as exposure to secondhand smoke, air pollution, and occupational hazards like asbestos are mostly responsible for this increase. Lung cancer cases are on the rise due in part to the growing number of individuals at risk for the disease as the population ages. Furthermore, improvements in early detection rates have been made possible by advances in medical diagnostics, which means that more patients are receiving a diagnosis at a point when surgery is both feasible and essential. The need for surgical procedures rises as a result of this expanding patient base, propelling market growth.

High cost of lung cancer diagnosis and treatment hinder market growth

Diagnostic procedures such as PET scans, CT scans, biopsies, and genetic testing are expensive, often costing thousands of dollars. Surgical procedures, such as pneumonectomies, lobectomies, and minimally invasive surgeries, demand an important financial investment for postoperative care, hospital stays, and surgical competence. Many patients require adjuvant medicines like chemotherapy and radiation in addition to surgery, which raises the total cost of care. These costs can discourage patients from getting timely, thorough care, especially in areas where insurance and money for healthcare are scarce. As a result, high expenses may cause misdiagnosis, lower treatment adherence, and eventually impede market expansion.

Technological advancements in lung cancer surgery present significant opportunities

Technological advancements like robotic-assisted surgery and minimally invasive methods have completely changed the surgical profession by giving doctors more control, precision, and access to hard-to-reach lung regions. With the use of these technologies, treatments become less intrusive, which improves patient outcomes overall and results in shorter recovery times and fewer complications. Furthermore, more precise tumor localization and margin assessment are made possible by developments in imaging technology, such as intraoperative and 3D imaging, which raise surgical success rates.

Competitive Landscape

The Lung Cancer Surgery market is characterized by the presence of several key players striving to enhance their market share through innovations, strategic partnerships, and mergers and acquisitions. Leading businesses that provide cutting-edge surgical solutions and technologies include Medtronic, Intuitive Surgical, Olympus Corporation, and Johnson & Johnson. With the goal of enhancing patient outcomes and shortening recovery periods, these businesses heavily engage in research and development to introduce robotically assisted operations, minimally invasive surgical techniques, and state-of-the-art diagnostic technologies. Furthermore, continuing clinical trials and partnerships with healthcare facilities are essential for advancing research and receiving regulatory approvals. Additionally, as regional and rising firms increase their product offerings and market share, the industry is seeing a rise in rivalry. These businesses concentrate on local production and affordable solutions to meet the expanding demand in emerging nations. Businesses are anticipated to prioritize precision surgery and personalized medicine as the industry develops, strengthening their competitive advantage by providing specialized solutions that cater to certain patient requirements and ailments.

The key players in the global Lung Cancer Surgery market include - Intuitive Surgical Inc. (U.S.) among others.

Recent Market Developments

UKs Surgical Instruments Group Holdings to Invest ₹231 Crore in Cutting-Edge Facility in Hyderabad for Indian Market Entry

• In 2024, UK-based Surgical Instruments Group Holdings (SIGH) plans to invest ₹231 crore in building a state-of-the-art manufacturing facility in Hyderabad within the next two to three years. This move signifies SIGHs entry into the Indian market and highlights its global expansion aspirations. The facility will address the gap in the Indian medical device sector by producing a wide range of instruments, including general surgical tools, precision instruments for micro-surgeries, orthopaedic power tools, dermatomes for maxo surgery, ophthalmic instruments, and minimal invasive surgery devices.

Clinithink and AstraZeneca Collaborate to Enhance Early Detection of Lung Cancer

• In 2023, Clinithink and AstraZeneca Oncology UK have joined forces for a fresh initiative employing artificial intelligence to pinpoint individuals in the early stages of lung cancer. The aim is to ensure prompt treatment, thus improving patient outcomes significantly.

The global Lung Cancer Surgery market can be categorized as Surgical Devices, Surgical Procedures, and Region.

Frequently Asked Questions (FAQs)?

1. What are the different types of surgeries used to treat lung cancer?

There are various surgical procedures such as Thoracotomy (lobectomy, Sleeve Resection, pneumonectomy, segmentectomy) and Minimally Invasive Surgeries. Minimally invasive techniques such as Video-Assisted Thoracoscopic Surgery (VATS) and robotic-assisted surgery offer advantages like quicker recovery and reduced post-operative discomfort, making them preferred options when feasible. Each approach aims to effectively treat lung cancer while minimizing impact on lung function and promoting patient recovery.

1. How have technological advancements in lung cancer surgery impacted patient outcomes and treatment effectiveness?

Technological advancements like robotic-assisted surgery and minimally invasive methods have completely changed the surgical profession by giving doctors more control, precision, and access to hard-to-reach lung regions. With the use of these technologies, treatments become less intrusive, which improves patient outcomes overall and results in shorter recovery times and fewer complications.

1. What are the anticipated trends and innovations expected to shape the Surgical Instruments segment in the lung cancer surgery market over the forecast period?

Advances in molecular profiling and genetic testing enable personalized treatment approaches. Targeted therapies and immunotherapies are integrated with surgery to tailor treatment plans based on individual tumor characteristics, enhancing effectiveness.

Robotic-assisted surgical systems are gaining popularity in lung cancer surgery due to their precision, dexterity, and advanced visualization capabilities. Surgeons utilize these systems for complex procedures, achieving higher accuracy and improved patient outcomes. Also, there is a shift towards patient-centered care models emphasizing patient preferences, quality of life, and holistic well-being. Surgeons engage patients in treatment decisions and provide comprehensive support services to address their physical, emotional, and psychosocial needs throughout the treatment journey.

1. How does the competitive landscape look like in the Lung Cancer Surgery?

The market is highly fragmented with multiple key players actively seeking to expand their market presence through innovation, strategic partnerships, and mergers and acquisitions. Prominent companies such as Medtronic, Intuitive Surgical, Olympus Corporation, and Johnson & Johnson lead the industry by offering advanced surgical solutions and cutting-edge technologies.